News & Updates

June 5, 2025

We're proud to share that SummaCor, Inc. has been selected to join the 2025 MedTech Innovator cohort, the world's largest accelerator for medical device companies. This recognition reflects the incredible work of our team and validates the potential of our solution to make a meaningful impact on healthcare. Over the next few months, we'll be participating in corporate mentorship, virtual accelerator programming (including coaching, tailored programming, and industry events) designed to accelerate our growth—and we're excited to bring the whole team along for the journey.

January 5, 2025

During the THT 2025 Shark Tank event in Boston, SummaCor pitched its innovative ideas to a panel of healthcare and technology experts. Although we did not win the competition, the valuable feedback—and the subsequent coverage in the JACC: Basic to Translational Science journal—highlighted our potential and opened new avenues for collaboration and growth. This pitch competition is known for accelerating breakthrough solutions in heart therapy technology.

October 28, 2024

At TCT 2024, one of the premier conferences for transcatheter cardiovascular therapeutics, SummaCor engaged with leading clinicians, researchers, and industry experts in Washington D.C. Our presentation highlighted breakthrough minimally invasive therapies and the next generation of cardiovascular innovations, reflecting the conference’s mission to drive cutting-edge advancements in interventional cardiology.

September 30, 2024

HFSA 2024 was set to unite healthcare professionals, researchers, and financial experts focused on advancing heart failure research and patient care. Unfortunately, the event in Atlanta was canceled due to the unforeseen impact of Hurricane Helene, which disrupted travel and venue operations. We remain committed to fostering collaboration in the field and look forward to future HFSA gatherings.

June 22, 2024

CSI 2024 in Frankfurt provided an international forum for experts in cardiovascular structural interventions. Throughout the week, industry leaders discussed the latest device innovations and clinical strategies to tackle structural heart disease. SummaCor’s session underscored our commitment to improving patient outcomes through pioneering technology and evidence-based practice.